What are the indications, dosing regimen, contraindications, and precautions for fesoterodine fumarate?

Fesoterodine Fumarate: Clinical Overview

Fesoterodine fumarate is a second-line antimuscarinic agent indicated for overactive bladder (OAB) in adults and neurogenic detrusor overactivity (NDO) in pediatric patients aged 6 years and older, dosed at 4 mg once daily with optional titration to 8 mg for enhanced symptom control. 1

Indications

Fesoterodine is FDA-approved for:

• Adult overactive bladder (OAB) with symptoms of urinary frequency, urgency, and urgency urinary incontinence 1
• Pediatric neurogenic detrusor overactivity (NDO) in patients aged 6 years and older 1

Per AUA/SUFU guidelines, fesoterodine is positioned as second-line therapy after behavioral interventions (bladder training, pelvic floor exercises, fluid management) have been attempted first 2. Behavioral therapies should be offered initially as they are equally or more effective than antimuscarinics for reducing incontinence episodes and improving quality of life, without the medication side effects 2.

Dosing Regimen

Adult Patients with OAB

• Starting dose: 4 mg once daily 1
• Titration: May increase to 8 mg once daily based on individual response and tolerability 1
• The 8 mg dose demonstrates superior efficacy compared to 4 mg, with significantly greater reductions in urgency urinary incontinence episodes, micturitions, and urgency episodes, plus higher diary-dry rates 3

Pediatric Patients (≥6 years) with NDO

• Dosing follows age-appropriate protocols as outlined in FDA labeling 1

Renal Impairment

• Severe renal impairment (CrCl <30 mL/min): Maximum 4 mg once daily 1
• Moderate impairment: No specific dose adjustment required, but monitor closely 1

Drug Interactions

• With potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): Maximum 4 mg once daily 1, 4
  • Coadministration increases 5-hydroxymethyl tolterodine (active metabolite) exposure approximately 2-fold in extensive metabolizers and 2.5-fold in poor metabolizers 4
• With CYP3A4 inducers (e.g., rifampicin): Avoid combination as it may produce subtherapeutic drug levels 4

Administration

• Take with or without food 1
• Swallow tablets whole; do not crush, chew, or divide 1

Contraindications

Absolute contraindications include:

• Urinary retention 1
• Gastric retention 1
• Uncontrolled narrow-angle glaucoma 1

Precautions and Warnings

Critical Safety Concerns

Angioedema: Can occur after first or subsequent doses; discontinue immediately if tongue, hypopharynx, or larynx involvement occurs 1.

Urinary retention: Use extreme caution in patients with:

• Bladder outlet obstruction 2, 1
• Clinically significant post-void residual urine 2
• Obtain specialist clearance (urologist) before initiating in at-risk patients 2
• Consider measuring post-void residual in patients suspected of retention risk 2

Decreased gastrointestinal motility: Use with extreme caution in:

• Impaired gastric emptying 2, 1
• Severe constipation 1
• Obtain gastroenterologist clearance before initiating in at-risk patients 2
• Contraindicated with solid oral potassium chloride due to increased potassium absorption risk 2

Narrow-angle glaucoma: Do not use unless approved by treating ophthalmologist 2, 1.

Central nervous system effects:

• Monitor for cognitive impairment, confusion, hallucinations, and somnolence 1
• Fesoterodine has poor blood-brain barrier penetration, which theoretically reduces CNS side effects 5
• Studies in Parkinson's disease patients showed stable cognitive function with 4 mg dosing 6

Myasthenia gravis: May worsen symptoms; use with caution 1.

Common Adverse Effects

The most frequent side effects are dose-dependent and generally mild-to-moderate 3:

• Dry mouth: 5.4-26.1% (dose-dependent: 12.9% at 4 mg, 26.1% at 8 mg) 3, 7
• Constipation: 1.5% 7
• Urinary tract infection 2
• Micturition disorder: 1.1% 7
• Blurred vision, dry eyes, dyspepsia 2

Discontinuation rates due to adverse events remain low across all doses 3.

Clinical Efficacy Considerations

• Dose-response relationship: The 8 mg dose provides statistically and clinically superior outcomes compared to 4 mg across all efficacy measures 3
• Flexible dosing strategy: Start all patients at 4 mg; titrate to 8 mg for those requiring optimal symptom relief 3
• Patients with more severe baseline symptoms experience greater absolute reductions 2
• Complete symptom resolution is more likely in patients with lower baseline symptom severity 2
• Behavioral therapies may be combined with fesoterodine for enhanced outcomes 2

Special Populations

• Elderly patients: Fesoterodine is classified as beneficial (LUTS-FORTA 2014 Class B) with proven efficacy and limited safety concerns in older adults 5
• Neurogenic populations: Effective in spinal cord injury and multiple sclerosis patients with neurogenic detrusor overactivity 8
• Pregnancy/Lactation: Refer to FDA labeling for specific guidance 1

Treatment Algorithm

1. First-line: Initiate behavioral therapies (bladder training, pelvic floor exercises, fluid/caffeine reduction, weight loss if obese) 2
2. Second-line: If behavioral therapy insufficient, start fesoterodine 4 mg once daily 2, 1
3. Dose optimization: After 4 weeks, if inadequate response and tolerability is acceptable, increase to 8 mg once daily 3
4. Monitoring: Assess post-void residual if retention risk exists; monitor for anticholinergic side effects 2
5. Third-line: If refractory to behavioral and antimuscarinic therapy after adequate trial, refer to specialist for neuromodulation or onabotulinumtoxinA 2